bryostatin 10: isolated from Bugula neritina; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Bugula | genus | [no description available] | Lamiaceae | The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 9962496 |
| CHEMBL ID | 501262 |
| MeSH ID | M0263772 |
| Synonym |
|---|
| bryostatin 10 |
| CHEMBL501262 , |
| bdbm50292348 |
| [(1s,3s,5z,7r,8e,11r,13e,15s,17r,21r,23r,25s)-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-25-yl] 2,2-dimethylpropanoate |
| Excerpt | Relevance | Reference |
|---|---|---|
| "05) for Weeks #13 through #42, even 16 weeks after dosing completion by Week #26." | ( Advanced Alzheimer's Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial. Alkon, DL; Sun, MK; Thompson, RE; Tuchman, AJ, 2023) | 0.91 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Protein kinase C alpha type | Homo sapiens (human) | Ki | 0.0016 | 0.0002 | 1.0945 | 6.9600 | AID400689 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| ciliary basal body | Protein kinase C alpha type | Homo sapiens (human) |
| nucleoplasm | Protein kinase C alpha type | Homo sapiens (human) |
| cytoplasm | Protein kinase C alpha type | Homo sapiens (human) |
| mitochondrion | Protein kinase C alpha type | Homo sapiens (human) |
| endoplasmic reticulum | Protein kinase C alpha type | Homo sapiens (human) |
| cytosol | Protein kinase C alpha type | Homo sapiens (human) |
| plasma membrane | Protein kinase C alpha type | Homo sapiens (human) |
| mitochondrial membrane | Protein kinase C alpha type | Homo sapiens (human) |
| perinuclear region of cytoplasm | Protein kinase C alpha type | Homo sapiens (human) |
| extracellular exosome | Protein kinase C alpha type | Homo sapiens (human) |
| alphav-beta3 integrin-PKCalpha complex | Protein kinase C alpha type | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID400689 | Displacement of [3H]PDBu form PKCalpha | 1996 | Journal of natural products, Mar, Volume: 59, Issue:3 | Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. |
| AID360584 | Increase in ACTH-induced steroidogenesis in bovine adrenocortical cells measured per 10'5 cells | 1995 | Journal of natural products, Dec, Volume: 58, Issue:12 | An improved source of bryostatin 10, Bugula neritina from the Gulf of Aomori, Japan. |
| AID360581 | Inhibition of fertilized sea urchin egg cell division | 1995 | Journal of natural products, Dec, Volume: 58, Issue:12 | An improved source of bryostatin 10, Bugula neritina from the Gulf of Aomori, Japan. |
| AID360580 | Cytotoxicity against mouse P388 cells | 1995 | Journal of natural products, Dec, Volume: 58, Issue:12 | An improved source of bryostatin 10, Bugula neritina from the Gulf of Aomori, Japan. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||